Volume 2.37 | Sep 20

Hematopoiesis News 2.37, September 20, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY

The Role of Skp2 in Hematopoietic Stem Cell Quiescence, Pool Size and Self-Renewal
Here scientists show that Skp2, a component of the Skp2 SCF complex, is an important regulator for hematopoietic stem cell quiescence, frequency, and self-renewal capability. [Blood] Abstract

ON161-STEMvisionCC_645x110

PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Directional DNA Methylation Changes and Complex Intermediate States Accompany Lineage Specificity in the Adult Hematopoietic Compartment
Here, researchers have characterized the methylomes of human female hematopoietic stem/progenitor cells and mature cells from the myeloid and lymphoid lineages. [Mol Cell] Abstract


Epigenetic and Molecular Profiles of Erythroid Cells Following Hydroxyurea Treatment in Sickle Cell Anemia
In this current study, scientists investigated potential epigenetic and alternative molecular mechanisms of hydroxyurea-mediated fetal hemoglobin induction by examining methylation patterns within the Gγ-globin promoter and miRNA expression within primary CD71+ erythrocytes of patients with Sickle Cell Anemia, both at baseline before beginning hydroxyurea therapy and after reaching maximum tolerated dose. [Blood] Abstract


Multiple HLA Class I and II Associations in Classical Hodgkin Lymphoma and EBV Status Defined Subgroups
To explore the role of the human leukocyte antigen (HLA) genes, scientists performed a case-control genotyping study in 338 Dutch classical Hodgkin lymphoma patients and more than 5,000 controls using a PCR-based sequence-specific oligonucleotide probe hybridization approach. [Blood] Abstract

Optimized Anti-Tumor Effects of Anthracyclines Plus Vinca Alkaloids Using a Novel, Mechanism-Based Application Schedule
Here investigators show for the first time that both drugs (anthracyclines and vinca alkaloids) might act most efficiently, if they are applied on different days. [Blood] Abstract

A Promoter DNA Demethylation Landscape of Human Hematopoietic Differentiation
Here, researchers show that promoter DNA demethylation is associated with the activation of hematopoietic-specific genes. [Nucleic Acids Res] Abstract


LPA Induces Erythropoiesis through Activating LPA Receptor 3
In this study, investigators found that erythroblasts expressed both lysophosphatidic acid (LPA) receptor 1 (LPA1) and LPA3, and erythropoietic defects were observed in zLPA3 antisense morpholino oligonucleotide-injected zebrafish embryos. [Stem Cells] Abstract

A Comprehensive Study of Polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 Genes and Lymphoma Risk
Using a tagging approach, scientists tested the hypothesis that common polymorphisms in the transporter genes ABCB1, ABCC2, ABCG2, and the regulator gene NR1I2 could be implicated in lymphoma risk. [Int J Cancer] Abstract

CLINICAL RESEARCH

Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Prolonged Remission with Imatinib Treatment
Researchers evaluated BCR-ABL expression in CD34+CD38+ committed progenitors and CD34+CD38 stem/primitive progenitor cells in samples from chronic myelogenous leukemia patients on imatinib mesylate treatment for at least 4 years with cytogenetic and molecular response. [Blood] Abstract


Phase II Study of PVAG (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) in Elderly Patients with Early Unfavorable or Advanced Stage Hodgkin Lymphoma
In this multicenter phase II study, elderly Hodgkin Lymphoma patients in early unfavorable and advanced stages received 6-8 cycles PVAG and additional radiotherapy if they were not in CR after chemotherapy. [Blood] Abstract


Allogeneic Stem Cell Transplantation for Patients Harboring T315I BCR-ABL Mutated Leukemias
Investigators report the outcome of allogeneic SCT in 64 patients with documented BCR-ABLT315I mutations. [Blood] Abstract


IDH Mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F
Isocitrate dehydrogenase (IDH) mutations are frequent in blast-phase myeloproliferative neoplasms and might therefore contribute to leukemic transformation. Researchers examined this possibility in 301 consecutive patients with chronic-phase primary myelofibrosis. [Leukemia] Abstract

ON176-PrimaryCells_645x110_V2

INDUSTRY NEWS

HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase II Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
HemaQuest Pharmaceuticals, Inc. announced that it has completed enrollment in a randomized multi-dose Phase II study of HQK-1001 in patients with sickle cell disease. [HemaQuest Pharmaceuticals, Inc] Press Release

ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders
Advanced Cell Technology (ACT), Inc. announced that it has been issued a patent (patent number 8,017,393) for the Company’s proprietary method for generating and expanding hemangioblast cells from human embryonic stem cells. [Advanced Cell Technology, Inc] Press Release

Genetics Policy Institute Announces 2011 “Stem Cell Action” Award Winners and Honorees
The Genetics Policy Institute will honor individuals and organizations that have positively impacted the advancement of stem cell research at the 7th Annual Stem Cell Action Awards Dinner on October 4, 2011. [Genetic Engineering & Biotechnology News] Press Release

POLICY NEWS

South Korea Sets Sights on Becoming Stem Cell Powerhouse, Again
South Korea’s president vowed on a series of regulatory reforms to help regain its place as a stem cell research powerhouse, trying to reclaim momentum five years after a cloning scandal. [South Korea President, South Korea] Press Release


National Heart, Lung, and Blood Institute; Notice of Meeting (FR Doc No: 2011-23654) [National Institutes of Health, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW VI Brazilian Congress on Stem Cells and Cell Therapy
September 28-October 1, 2011
Salvador, Brazil

NEW 22nd Regional Congress of the ISBT
November 19-23, 2011
Taipei, Taiwan

NEW 32nd International Congress of the ISBT
July 7-12, 2012
Cancun, Mexico

Visit our events page to see a complete list of events in the hematopoietic community

JOB OPPORTUNITIES
Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist (STEMCELL Technologies)

Director, Hematopoietic Stem Cell Transplant Program (University of Chicago)

Postdoctoral Position (Izmir Katip Celebi University)

Postdoctoral Positions in Stem Cells and Immunology (University of Connecticut)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us